Henogen opens new biopharmaceutical clinical supply plant
This investment extends the existing know-how of Henogen 'from gene to clinical product' to the large scale production of clinical grade monoclonal antibodies and recombinant proteins made by mammalian cells, which is a very fast growing market.
These new facilities will generate additional revenues to the existing ones (forecast 2004: 7 MEUR) in order to boost the clinical development of its proprietary products e.g. a recombinant human tissue factor derivative, currently in clinical trials as well as other undisclosed programs.
Most read news
Topics
Organizations
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous